News
Why GoodRx (GDRX) Stock Is Trading Up Today
Shares of healthcare tech company GoodRx (NASDAQ:GDRX) jumped 40.2% in the afternoon session after the company announced a collaboration with pharmaceutical giant Novo Nordisk to offer the popular medications Ozempic and Wegovy for $499 per month to eligible self-paying customers.
GoodRx is joining the GLP-1 action with an announcement Monday to begin selling both Novo Nordisk's GLP-1 drugs, Ozempic and ...
GoodRx Holdings, Inc.'s partnership with Novo Nordisk highlights its vital role in direct-to-consumer drug pricing. Click ...
Cash-paying type 2 diabetes patients in the United States can now access Novo Nordisk's Ozempic for $499 per month through ...
Bloomberg on MSN1h
GoodRx Expands Access to Ozempic
GoodRx shares soar after announcing the company's partnership with Novo Nordisk to slash the cost of Ozempic. GoodRx CEO ...
The transaction is led by MCR Investors and its Chairman and CEO, Tyler Morse, with financing from Apollo and Goldman Sachs ...
Patients who are prescribed Wegovy or Ozempic can now use GoodRx to access the medications at just $499 a month if they skip ...
GoodRx Holdings Inc. (NASDAQ:GDRX) announced that, via a collaboration with Novo Nordisk A/S (NYSE:NVO), all strengths of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback